Zoetis Inc. (NYSE:ZTS) Shares Sold by TD Asset Management Inc.

TD Asset Management Inc. lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 4.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,618,309 shares of the company's stock after selling 79,160 shares during the period. TD Asset Management Inc. owned 0.36% of Zoetis worth $263,671,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Mission Wealth Management LP increased its holdings in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after purchasing an additional 59 shares during the last quarter. Hancock Whitney Corp grew its holdings in Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company's stock valued at $3,628,000 after buying an additional 61 shares in the last quarter. VeraBank N.A. increased its stake in shares of Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after acquiring an additional 62 shares during the last quarter. HUB Investment Partners LLC raised its holdings in shares of Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after acquiring an additional 62 shares during the period. Finally, Procyon Advisors LLC boosted its position in shares of Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after acquiring an additional 63 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Remove Ads

Zoetis Trading Down 1.2 %

NYSE:ZTS traded down $1.99 on Friday, reaching $163.03. 1,550,283 shares of the company's stock were exchanged, compared to its average volume of 2,595,079. The firm has a market capitalization of $73.00 billion, a price-to-earnings ratio of 29.80, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The business has a fifty day moving average of $166.40 and a 200-day moving average of $174.55.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. As a group, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.23%. Zoetis's payout ratio is 36.56%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Barclays lifted their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Stifel Nicolaus decreased their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Morgan Stanley lowered their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Piper Sandler upped their price target on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Finally, Leerink Partnrs upgraded Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $215.90.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock worth $312,254 in the last quarter. 0.16% of the stock is owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.